Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

Next Previous
X
Search
Trial Profile

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INZ-701 (Primary)
  • Indications Calcinosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ENERGY-3
  • Sponsors Inozyme Pharma

    • Most Recent Events

    • 10 Mar 2025 According to an Inozyme Pharma media release, topline data from this trial expected in first quarter of 2026
    • 10 Jan 2025 According to an Inozyme Pharma media release, the company anticipates completing the one-year dosing period for all patients by January 2026
    • 10 Jan 2025 Status changed from recruiting to active, no longer recruiting, as per Inozyme Pharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top